Variant, Immune Signatures, DNA Methylation, and Social Determinants Linked to Survival Racial Disparities in Head and Neck Cancer Patients.

Title Variant, Immune Signatures, DNA Methylation, and Social Determinants Linked to Survival Racial Disparities in Head and Neck Cancer Patients.
Publication TypeJournal Article
Year of Publication2019
AuthorsGuerrero-Preston R, Lawson F, Rodriguez-Torres S, Noordhuis MG, Pirini F, Manuel L, Valle BL, Hadar T, Rivera B, Folawiyo O, Baez A, Marchionni L, Koch WM, Westra WH, Kim YJ, Eshleman JR, Sidransky D
JournalCancer Prev Res (Phila)
Volume12
Issue4
Pagination255-270
Date Published2019 04
ISSN1940-6215
KeywordsAdult, African Americans, Biomarkers, Tumor, Case-Control Studies, DNA Methylation, European Continental Ancestry Group, Female, Follow-Up Studies, Gene Expression Regulation, Neoplastic, Germ-Line Mutation, Head and Neck Neoplasms, Health Status Disparities, Humans, Janus Kinase 3, Lymphocytes, Tumor-Infiltrating, Male, Middle Aged, Prognosis, Social Determinants of Health, Squamous Cell Carcinoma of Head and Neck, Survival Rate, Tumor Suppressor Protein p53
Abstract

To inform novel personalized medicine approaches for race and socioeconomic disparities in head and neck cancer, we examined germline and somatic mutations, immune signatures, and epigenetic alterations linked to neighborhood determinants of health in Black and non-Latino White (NLW) patients with head and neck cancer. Cox proportional hazards revealed that Black patients with squamous cell carcinoma of head and neck (HNSCC) with ( = 0.06) and ( = 0.017) promoter methylation had worse survival than NLW patients, after controlling for education, zipcode, and tumor-node-metastasis stage ( = 118). We also found that promoter methylation of and P ( = 78), was correlated with neighborhood characteristics at the zip-code level ( < 0.05). Analyses also showed differences in the frequency of mutations ( = 32) and tumor-infiltrating lymphocyte (TIL) counts ( = 24), and the presence of a specific C → A germline mutation in , chr19:17954215 (protein P132T), in Black patients with HNSCC ( = 73; < 0.05), when compared with NLW ( = 37) patients. TIL counts are associated ( = 0.035) with long-term (>5 years), when compared with short-term survival (<2 years). We show bio-social determinants of health associated with survival in Black patients with HNSCC, which together with racial differences shown in germline mutations, somatic mutations, and TIL counts, suggests that contextual factors may significantly inform precision oncology services for diverse populations.

DOI10.1158/1940-6207.CAPR-17-0356
Alternate JournalCancer Prev Res (Phila)
PubMed ID30777857
PubMed Central IDPMC6800037
Grant ListR01 CA121113 / CA / NCI NIH HHS / United States
K12 GM102779 / GM / NIGMS NIH HHS / United States
K01 CA164092 / CA / NCI NIH HHS / United States
P50 DE019032 / DE / NIDCR NIH HHS / United States
RC2 DE020957 / DE / NIDCR NIH HHS / United States
U01 CA084986 / CA / NCI NIH HHS / United States
Related Faculty: 
Luigi Marchionni, M.D., Ph.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700